Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5R01DK135000 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Children's Hospital Los Angeles | OTHER |
| University of California, Davis | OTHER |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
Not provided
Not provided
Not provided
Not provided
Diabetes technology, such as insulin pumps and continuous glucose monitoring devices, can help improve glucose control for people with type 1 diabetes (T1D), which keeps them at lower risk for diabetes complications, but many Latinx adolescents, who make up the largest marginalized ethnic group of youth with T1D in California, use these devices less often and have less optimal glucose control compared to White youth. In phase 1 of this project, we worked directly with Latinx youth, their families, and diabetes care team members in California to develop DREAM, Device use Reimagined through Education And Mentorship, a virtual peer group (VPG) intervention that will encourage and support the use of diabetes devices in Latinx adolescents with T1D. The goals for phase 2 (intervention) of this project are to evaluate the feasibility and acceptability of the stakeholder-informed VPG intervention, and evaluate clinical and person-centered outcomes.
This multi-site project has two phases: phase 1 involved stakeholders focus groups to assess barriers and facilitators to diabetes technology and the creation of advisory councils. Feedback was obtained and used to develop phase 2, the single arm trial. A virtual peer group curriculum is being refined and will be implemented. The aims of this project are: (1) Partner with stakeholders to design a virtual peer group (VPG) intervention to promote the initiation and continued use of diabetes technology among Latinx adolescents with T1D. (2) Evaluate the feasibility and acceptability of DREAM VPGs in a pragmatic, single arm trial. (3) Assess the effects of DREAM VPGs on clinical and person-centered outcomes.
Our DREAM intervention will:
The DREAM project's findings will inform future efforts to improve diabetes technology use and T1D health outcomes among Latinx adolescents. If found to be effective, the VPG curriculum can be adapted for other clinic settings in order to improve education and peer support for Latinx patients and families. Future studies may extend or adapt DREAM to other cohorts, including other age groups, geographic settings, or marginalized and historically excluded populations with T1D.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Virtual peer groups (VPGs) Six different VPGs topics will be offered. Each VPG topic will be presented separately to youth and caregivers, in Spanish and English. Frequency of scheduling for each VPG will vary on a month-to-month basis depending on the distribution of current enrollees who have not yet discussed that topic and the availability of the relevant facilitators. In-Person Events Optional in-person events may be offered quarterly during the 6-12 month study participation period. |
|
| Comparator Group | No Intervention | An equal number of eligible non-enrolled patients at each site will be selected and matched to the enrolled cohort based on age, language, HbA1c, insurance type, and diabetes technology use at a population level. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DREAM intervention | Behavioral | Virtual Peer Groups (VPGs) Participants will have multiple opportunities to attend a VPG on a specific topic during their 6-12 month participation period. The VPG topics will include the following:
In-Person Events will be held quarterly to facilitate participant interaction and community-building. These gatherings will feature ice-breaker activities, refreshments, and hands-on learning opportunities, including the chance to interact with specific diabetes devices and engage with healthcare professionals and representatives from diabetes technology companies. |
| Measure | Description | Time Frame |
|---|---|---|
| Caregiver Survey | Captures personal and family background (e.g. gender, income) | Baseline |
| Caregiver Phase 2 Intervention Survey - "Feedback Survey" | Assess various intervention components (e.g., frequency of virtual peer groups, in person events). | End of Study to (6-15 months) |
| Caregiver In Person Event Evaluation | Captures in the moment in person event feedback (e.g., improve experience and components). | Throughout the study, up to 15 months |
| Caregiver Online Group Evaluation | Captures moment group feedback (e.g., improve experience and content). | Throughout the study, up to 15 months |
| Adolescent Survey | Captures diabetes technology, personal and family background (e.g., diabetes technology history, gender). | Baseline |
| Adolescent Phase 2 Intervention Survey - "Feedback Survey" | Assess various intervention components (e.g, frequency of virtual peer groups, in person events). | End of Study (6-15 months) |
| Adolescent In Person Event Evaluation | Captures in the moment in person event feedback (e.g., improve experience and components). | Throughout the study, up to 15 months |
| Measure | Description | Time Frame |
|---|---|---|
| Caregiver Diabetes Distress Scale (DDS) | Measures parent-related distress, person distress, teen management distress, parent/teen relationship distress and healthcare distress, response options for each item were provided on a 5-point Likert scale, higher score indicated more distress. | Baseline and End of Study (6-15 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Socio-Demographic History | Self-reported demographic history (gender, age, race, household income, etc) will be collected. | Baseline |
| Diabetes Technology Use | Diabetes technology use history self-reported and Electronic Medical Record (EMR) Abstraction |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jenise C Wong, MD, PhD | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Davis | Davis | California | 95616 | United States | ||
| Children's Hospital Los Angeles |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26869664 | Background | Hessler D, Fisher L, Polonsky W, Johnson N. Understanding the Areas and Correlates of Diabetes-Related Distress in Parents of Teens With Type 1 Diabetes. J Pediatr Psychol. 2016 Aug;41(7):750-8. doi: 10.1093/jpepsy/jsw002. Epub 2016 Feb 10. | |
| 32028790 | Background | Manning ML, Singh H, Stoner K, Habif S. The Development and Psychometric Validation of the Diabetes Impact and Device Satisfaction Scale for Individuals with Type 1 Diabetes. J Diabetes Sci Technol. 2020 Mar;14(2):309-317. doi: 10.1177/1932296819897976. Epub 2020 Feb 6. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Intervention group (will receive VPG curriculum) versus comparator group (not enrolled)
Not provided
Not provided
Not provided
Not provided
|
| Adolescent Online Group Evaluation |
Captures moment group feedback (e.g., improve experience and content). |
| Throughout the study, up to 15 months |
| Attendance at VPG and in-person events | Attendance will be recorded for each in person and online events | Throughout the study, up to 15 months |
| Retention of enrolled patients | Engagement of participants throughout study trajectory | End of Study (6-15 months) |
| Caregiver Diabetes Family Conflict Scale (DFCS) |
Measures negative emotions around BGM, quality of life, and perceived parental burden from diabetes management; 3-point Likert scale, higher score indicating more conflict. |
| Baseline and End of Study (6-15 months) |
| Caregiver Health Care Relationship (QHR) | Captures interactions with medical team, response options for each item were provided on a 5-point Likert scale in various formats. | Baseline and End of Study (6-15 months) |
| Patient Health Utilization | Asks about any interval ED or hospital utilization over the prior 3 months | Baseline, 3-months, 6-months, 9-months, End of Study 12 to 15-months |
| Adolescent Diabetes Distress Scale (DDS) | Measures diabetes emotional distress; response options for each item were provided on a 5-point Likert scale, higher score indicated more distress. | Baseline and End of Study (6-15 months) |
| Adolescent Benefits and Burdens of CGM (BenCGM & BurCGM) | Measures benefits and burdens of continuous glucose monitoring in adolescents; 5-point Likert scale. | Baseline and End of Study (6-15 months) |
| Adolescent Diabetes Family Conflict Scale, (DFCS) | Measures negative emotions around BGM, quality of life, and perceived parental burden from diabetes management, 3-point Likert scale, higher score indicating more conflict. | Baseline and End of Study (6-15 months) |
| Adolescent Diabetes Strengths and Resilience Measure (DSTAR) | Captures adaptive aspects of adolescents' diabetes management (i.e., "strengths"), and is related to clinical outcomes, 5-point Likert scale. | Baseline and End of Study (6-15 months) |
| Adolescent BenPump/Pod & BurPump/Pod | Measures benefits and burdens of pump/pods monitoring in adolescents, 5-point Likert scale. | Baseline and End of Study (6-15 months) |
| Baseline and End of Study (6-15 months) |
| Number of participants completing rountine appointments | Electronic Medical Record (EMR) Abstraction | Baseline and End of Study (6-15 months) |
| Hemoglobin A1c | Lab results | Baseline and End of Study (6-15 months) |
| Los Angeles |
| California |
| 90027 |
| United States |
| University of California, San Francisco | San Francisco | California | 94158 | United States |
| 15735199 | Background | Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, Jackson RA. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005 Mar;28(3):626-31. doi: 10.2337/diacare.28.3.626. |
| 30854886 | Background | Messer LH, Cook PF, Tanenbaum ML, Hanes S, Driscoll KA, Hood KK. CGM Benefits and Burdens: Two Brief Measures of Continuous Glucose Monitoring. J Diabetes Sci Technol. 2019 Nov;13(6):1135-1141. doi: 10.1177/1932296819832909. Epub 2019 Mar 10. |
| 17372149 | Background | Hood KK, Butler DA, Anderson BJ, Laffel LM. Updated and revised Diabetes Family Conflict Scale. Diabetes Care. 2007 Jul;30(7):1764-9. doi: 10.2337/dc06-2358. Epub 2007 Mar 19. |
| 31336011 | Background | Iturralde E, Hood KK, Weissberg-Benchell J, Anderson BJ, Hilliard ME. Assessing strengths of children with type 1 diabetes: Validation of the Diabetes Strengths and Resilience (DSTAR) measure for ages 9 to 13. Pediatr Diabetes. 2019 Nov;20(7):1007-1015. doi: 10.1111/pedi.12898. Epub 2019 Jul 29. |
| 28549160 | Background | Hilliard ME, Iturralde E, Weissberg-Benchell J, Hood KK. The Diabetes Strengths and Resilience Measure for Adolescents With Type 1 Diabetes (DSTAR-Teen): Validation of a New, Brief Self-Report Measure. J Pediatr Psychol. 2017 Oct 1;42(9):995-1005. doi: 10.1093/jpepsy/jsx086. |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |